Jun 11

AMRI second quarter total revenue increases 9 percent to $53.

Frost provided agreement revenue assistance for the third quarter and full calendar year 2011. ‘In the third quarter, we expect agreement revenue to range from $43 million to $47 million, a rise as high as 10 percent versus 2010. For the entire 12 months 2011, we continue to expect contract revenue to range between $179 million to $187 million, a rise of up to 15 percent versus 2010.’ Mr. Our practice will become revisited as we enter 2012. We estimate gross margins will become consistent with prior season while research and development expense is expected to decrease between 10-15 percent and offering, general and administrative expense should be flat to straight down ~5 percent with the prior year.’ Recent Highlights Recent noteworthy announcements or milestones at AMRI include the following: The effective completion of a Phase I clinical study on novel MCH1 receptor antagonist, ALB-127158.Blood Pressure The two therapeutic strategies quickly resulted in different systolic blood-pressure amounts . After the first year of therapy, the average systolic blood pressure at the 4-month protocol visits that both combined groups attended was 119.3 mm Hg in the intensive-therapy group and 133.5 mm Hg in the standard-therapy group, leading to the average between-group difference of 14.2 mm Hg . The corresponding mean diastolic blood pressures were 64.4 and 70.5 , for the average difference of 6.1 mm Hg . The lower blood pressure in the intensive-therapy group was connected with a greater contact with drugs from every class . The mean number of medications following the first yr was 3.4 in the intensive-therapy group and 2.1 in the standard-therapy group. Adverse Events As compared with the standard-therapy group, the intensive-therapy group had higher prices of serious adverse events related to antihypertensive treatment significantly, and also higher prices of hypokalemia and elevations in serum creatinine level .